Health care professionals are often stymied in how to treat patients with gastric or gastroesophageal junction (GEJ) cancers who become resistant to first-line therapy or who cannot tolerate treatment due to toxicities. Fortunately, emerging antibody conjugates that target HER2 have shown activity against such tumors.
Join an expert panel of clinicians from Memorial Sloan Kettering Cancer Center and the University of Leuven for an on-demand series exploring HER2 testing, care options, Trastuzumab resistance, and side effect management. Complete the pre-session questionnaire to customize your learning experience across four modules.
Expanding treatment options with ADCs in HER2-positive gastric or gastroesophageal junction adenocarcinoma
Module 1: Impact of HER2 testing and implications for prognosis
Module 2: Defining care for HER2+ gastric or GEJ cancer
Module 3: Moving beyond Trastuzumab resistance and unresectability
Module 4: Managing unique adverse events
Expanding treatment options with ADCs in HER2-positive gastric or gastroesophageal junction adenocarcinoma
Module 1: Impact of HER2 testing and implications for prognosis
Module 2: Defining care for HER2+ gastric or GEJ cancer
Module 3: Moving beyond Trastuzumab resistance and unresectability
Module 4: Managing unique adverse events
